🇺🇸

US SEC Filing Intelligence

· daily

Insider Trading Pulse — September 21, 2026

The September 21, 2026 insider trading digest reveals a mixed but actionable landscape. The most significant bearish signal is a concentrated wave of high-value insider selling at Dell Technologies, where the CFO and General Counsel collectively sold over $15.8M in stock near all-time highs, suggesting peak valuation concerns. Conversely, bullish conviction buying is evident in the energy and materials sectors, with the CEO of Borr Drilling and Executive Chairman of enCore Energy making substantial open-market purchases, signaling confidence in a cyclical recovery. A notable pattern of 'neutral' stock awards and option exercises across companies like Viasat, Evolution Petroleum, and Yum China indicates routine compensation, but the sheer volume of awards at Yum China (multiple C-suite executives) points to a major long-term incentive program. The most glaring risk flag is a director at Pharvaris N.V. selling 100% of his stake for $7M, a complete exit that warrants immediate scrutiny. Overall, the data suggests a 'risk-on' rotation into value/cyclicals (energy, financials) and away from high-growth tech (Dell, Palo Alto Networks), with several 'neutral' events masking potential insider sentiment shifts.

50 high priority 50 total filings
· daily

Dow Jones 30 Stocks SEC Filings — September 21, 2026

The single filing from Salesforce, Inc. for September 21, 2026, reveals a significant insider purchase by Director Kirk David Blair, who acquired $999,000 worth of common stock at $239.33 per share, increasing his holdings to 18,748 shares. This insider buying activity, given the material size of the transaction, signals strong management conviction in the company's near-term prospects and current valuation. With no other filings from Dow 30 constituents on this date, the digest focuses on this isolated but high-conviction signal. The purchase comes amid a period of heightened focus on enterprise software spending and AI monetization, suggesting Salesforce may be positioned for relative outperformance. The positive sentiment and director-level buying provide a bullish undercurrent for the stock, though broader sector trends remain absent due to the limited filing set.

1 high priority 1 total filings
· daily

US Corporate Distress Financial Stress SEC Filings — September 21, 2026

The September 21, 2026, snapshot reveals a bifurcated distress landscape in the US corporate arena: one company (Linkhome Holdings) successfully resolved its delisting risk by regaining Nasdaq bid price compliance, while another (Sangamo Therapeutics) completed a distressed asset sale post-Chapter 11, resulting in delisting and a transition to the OTC Pink Market. The 50% compliance-to-bankruptcy split within this two-filing sample underscores the binary outcomes inherent in distress situations, with Linkhome demonstrating that proactive balance sheet management can restore listing status, while Sangamo's trajectory highlights the value-destructive path of prolonged insolvency. Notably, neither filing contained period-over-period financial comparisons, insider trading activity, or forward-looking guidance, limiting quantitative trend analysis but emphasizing the event-driven nature of these disclosures. The most material development is Sangamo's $111M upfront asset sale, which, while providing a partial recovery for creditors, marks the end of its operations as a going concern and offers a stark contrast to Linkhome's positive compliance event. The absence of scheduled events in both filings suggests that investors must monitor OTC trading dynamics for Sangamo and ongoing Nasdaq listing standards for Linkhome. Overall, the data points to a market where regulatory compliance events and bankruptcy proceedings are the primary catalysts, with limited forward visibility, making event-driven and post-restructuring analysis critical for investors navigating this distressed landscape.

2 high priority 2 total filings
· daily

Global High-Priority Regulatory Events — September 21, 2026

Today's filings reveal a bifurcated market: a flurry of high-activity SPAC and M&A transactions (NCMI, Dixon, Himadri) signaling continued appetite for growth and consolidation, contrasted with significant stress in the healthcare and biotech sectors (Sangamo bankruptcy, Thyrocare divestiture, LHAI compliance). A notable trend is the increased use of related-party transactions and internal capital deployment (Dixon, Himadri, PSL, Adivistar) to drive vertical integration and expansion. While no single systemic risk dominates, the concentration of SPAC deadline extensions and the high materiality of the Sangamo bankruptcy warrant close monitoring. The overall sentiment is cautiously optimistic, with 3x more bullish signals than bearish, driven by strategic M&A and proactive capital management.

39 high priority 39 total filings
· daily

US SEC Filings Daily Market Digest — September 21, 2026

Today's 50 filings reveal a bifurcated tape: large-cap tech and financial institutions signal confidence via buybacks and insider accumulation, while consumer-facing and international names (HP, Cemex, BrasilAgro) show caution on demand and FX. Capital formation is robust—Axon's $1.0B convertible, AIAI's $200M equity facility, and a $15M IPO pipeline indicate open access to markets. Governance and legal overhangs (SEC/DOJ probes, arbitration awards) remain key risks. Key watch items: HP's fiscal 2027 guidance (absent), Axon's conversion premium, and the reopened tender offer for a target company.

21 high priority 29 medium 50 total filings
· daily

S&P 500 Consumer Discretionary Sector SEC Filings — September 21, 2026

The three filings in this Consumer Discretionary digest are all Form 4 insider activity reports, revealing a notable divergence in management sentiment across the sector. Insider selling by DoorDash's COO and Ulta Beauty's CEO, both executed under Rule 10b5-1 plans, signals potential concerns about current valuations or a desire for liquidity, while Chipotle's director stock award indicates continued board alignment with shareholders. The absence of any period-over-period financial data, forward-looking guidance, or capital allocation details in these filings limits the ability to identify fundamental trends, but the insider activity pattern is actionable. The prevalence of 10b5-1 plan sales suggests that the selling is pre-scheduled, yet the dollar amounts are material enough to warrant attention. The sector theme points to a bifurcation where executives at high-multiple growth names are de-risking, while a director at a value-oriented company is receiving equity compensation. Investors should monitor upcoming earnings calls for context on these transactions and watch for any acceleration in insider selling that could signal broader sector weakness.

3 high priority 3 total filings
· daily

S&P 500 Healthcare Sector SEC Filings — September 21, 2026

The sole filing in this digest is Medtronic plc's Form 425, an M&A communication regarding the proposed spin-off and exchange offer for its MiniMed diabetes business. While no financial figures are disclosed in the filing, the transaction is a significant corporate action that will reshape Medtronic's portfolio, creating a separately traded MiniMed Group, Inc. The exchange offer of up to 225 million shares signals a major capital markets event, and the filing's neutral sentiment reflects its procedural nature. This development is the single most critical event for the stream today, with implications for Medtronic's valuation, capital allocation, and sector positioning. No period-over-period comparisons, insider activity, or forward-looking guidance are available in this filing, limiting trend analysis but highlighting a discrete catalyst.

1 high priority 1 total filings
· daily

US Earnings Financial Results SEC Filings — September 21, 2026

The 11 filings reveal a bifurcated micro-cap landscape: while top-line growth is emerging in select monetization stories (AIRWA, Bloomia, QRED), the majority of filers remain pre-revenue or deeply unprofitable, with reliance on related-party financing and going-concern risks. Key themes include a shift toward asset-light subscription models, aggressive cost discipline (evidenced by reduced share-based comp), and a notable absence of insider buying despite equity raises. The most actionable signals are the 680% revenue surge at AIRWA (albeit from a low base) and the successful $115M SPAC IPO at QuasarEdge, which provides a rare cash-rich balance sheet. Conversely, the sector is plagued by deteriorating cash positions, widening stockholders' deficits, and one-off impairments, demanding rigorous balance-sheet scrutiny.

11 high priority 11 total filings
· daily

US IPO Pipeline SEC S-1 Filings — September 21, 2026

The IPO pipeline on September 21, 2026, features two distinct new registrations: Iambic Therapeutics, an AI-driven biopharmaceutical company, and Silicon Valley Acquisition Corp. II, a blank-check SPAC. Both filings are at the initial S-1 stage with no disclosed pricing or share counts, indicating early-stage capital formation. The biotech IPO signals continued investor appetite for AI-enabled drug discovery platforms, while the SPAC filing suggests renewed activity in the blank-check space despite regulatory headwinds. No period-over-period comparisons, insider activity, or forward-looking guidance are available from these initial filings, limiting trend analysis but highlighting the nascent nature of these offerings. The lack of financial metrics or operational history for either company underscores the speculative nature of early-stage IPO investments. Market implications center on the potential for Iambic's registrational trial catalyst in 2027 and SVAC II's ability to execute a de-SPAC transaction in a challenging market.

2 high priority 2 total filings
· daily

US SEC Trading Suspension Halt Orders — September 21, 2026

Linkhome Holdings Inc. (LHAI) successfully resolved its Nasdaq delisting risk by regaining compliance with the Minimum Bid Price Requirement, confirmed via an 8-K filing on September 18, 2026. The stock maintained a closing bid price above $1.00 for 10 consecutive business days (September 3–17, 2026), reversing the non-compliance notice received on June 29, 2026. This positive development removes an immediate overhang, though the company remains subject to ongoing Nasdaq listing standards. The resolution highlights the volatility and regulatory scrutiny typical of micro-cap stocks on the Nasdaq Capital Market. No other filings in this stream provide period-over-period comparisons, insider activity, forward-looking guidance, or capital allocation data, limiting the breadth of cross-company analysis.

1 high priority 1 total filings
· daily

US Executive Officer Management Changes SEC — September 21, 2026

The 43 filings reveal a significant wave of leadership transitions across US public companies, with 8 CEO changes and 7 CFO appointments announced on a single day (September 21, 2026). Key themes include orderly successions at major firms like Ethan Allen Interiors (CEO search by June 2027) and Beacon Financial (CEO Gray succeeding retiring Perrault), contrasted with sudden departures at PEDEVCO and Turning Point Brands. The data shows a clear sector skew toward financial services and healthcare in executive changes, with 5 director appointments bringing digital/tech expertise. Notably, 3 companies (SmartKem, Innventure, PEDEVCO) are using retention bonuses or enhanced severance to lock in leadership during strategic transitions, signaling potential instability. Forward-looking guidance was reaffirmed at QuickLogic and Turning Point Brands (tightened EBITDA range), while Innventure's aggressive cost-cutting (56% reduction) and SmartKem's $750K retention plan suggest financial stress. Insider activity is limited but notable: no insider purchases were reported, while CEO departures at PEDEVCO and Travere Therapeutics include significant separation packages, potentially dilutive to shareholders.

43 high priority 43 total filings
· daily

US Bankruptcy Chapter 11 Insolvency SEC Filings — September 21, 2026

This session is exceptionally quiet with only one filing in scope: Sangamo Therapeutics' 8-K confirming the final sale of its ST-920 gene therapy asset to PTC Therapeutics for $111M upfront plus up to $100M in milestones, following its Chapter 11 filing on June 23, 2026. The company's stock was delisted from Nasdaq on September 27, 2026, and now trades on the OTC Pink Market under SGMOQ. This marks the effective end of Sangamo as a going concern, with the bankruptcy process continuing solely for distribution to creditors. There are no period-over-period trends to aggregate across filings, no insider trading activity, no forward-looking guidance, and no capital allocation actions. The sole actionable insight is the confirmation of asset monetization at a material discount, signaling limited recovery for equity holders and a potential template for distressed gene therapy firms.

1 high priority 1 total filings
· daily

US Corporate Board Director Changes SEC Filings — September 21, 2026

This digest covers 43 filings related to USA Board Room Changes, with 29 new filings since the last brief. The dominant theme is a wave of CEO and C-suite transitions, including several high-profile departures and appointments at companies like Travere Therapeutics, Beacon Financial, and Turning Point Brands. A notable pattern is the internal promotion of CFOs and the creation of new board roles, such as Lead Independent Director at ENB Financial Corp. While most changes are routine, several filings contain forward-looking guidance adjustments, most critically at Turning Point Brands, which tightened its EBITDA guidance, and Innventure, which is implementing a 56% cost reduction. Insider activity is limited, but the compensation packages for new executives, particularly at Avantor and Travere, signal a focus on attracting top talent. The overall sentiment is neutral, with pockets of positive and mixed sentiment driven by strategic refocusing and succession planning. Key risks include the departure of long-tenured executives and the financial pressures at Innventure, while opportunities lie in the strategic refocusing at Beacon Financial and the board refreshment at PetMed Express.

43 high priority 43 total filings
· daily

USA Insider Trading Pulse — September 21, 2026

The September 21, 2026 insider trading pulse reveals a bifurcated market with significant insider selling in high-growth tech and consumer discretionary names, contrasted by strategic insider buying in undervalued energy, financial, and nuclear materials sectors. The most notable bearish signals come from **Dell Technologies** (CFO sold $13.5M), **Pharvaris N.V.** (director sold $7M), and **Palo Alto Networks** (director sold $1.79M), indicating potential top-side conviction or liquidity needs. On the bullish side, **Borr Drilling** (CEO bought $200K), **enCore Energy** (Executive Chairman bought $81K), and **Bank Bradesco** (executive bought $1M) signal strong management conviction in their respective cyclical and value plays. A dominant theme is the wave of routine equity awards and tax-withholding sales across companies like **Yum China**, **Enact Holdings**, and **VIASAT**, which are largely neutral but highlight ongoing compensation programs. No forward-looking guidance changes or major catalyst events were flagged in this batch, making the insider transactions themselves the primary actionable signal. The overall sentiment is cautiously bearish on growth names with insider selling, while value/cyclical sectors show insider accumulation, suggesting a potential rotation trade.

50 high priority 50 total filings
· daily

US Merger & Acquisition SEC Filings — September 21, 2026

The September 21, 2026 SPAC and M&A filing batch reveals a market characterized by intense time pressure on blank-check companies to finalize business combinations, with multiple extensions, bridge financings, and charter amendments signaling both urgency and resilience. The most material corporate actions include Axos Financial's completion of a $1.9 billion IRA deposit acquisition from Capital One, National CineMedia's $275 million acquisition of Captivate Holdings, and Algorhythm Holdings' transformational acquisition of an energy business accompanied by a CEO change. SPACs are increasingly using creative financing structures—prepaid forward purchase agreements, convertible promissory notes, and equity purchase facilities—to bridge funding gaps and de-risk redemptions, while also extending deadlines to buy time. Insider activity is limited but notable: the CEO dismissal at Algorhythm and the 100% sponsor ownership transfer at Ocean Capital warrant monitoring. Overall, the batch signals a bifurcated market: well-capitalized operating companies executing strategic M&A, while SPACs face a crunch to close deals before termination dates, with several facing imminent deadlines in October 2026.

12 high priority 12 total filings
· monthly

US Pre-Market SEC Filings Roundup — September 21, 2026

This pre-market digest covers 50 filings from the overnight period, revealing a market bifurcated between aggressive capital raising and significant legal/operational risks. Key themes include a surge in IPOs and equity financings (ADARx, Orion180, Fast Finance Pay, AIAI Holdings) alongside notable insider selling at Sea Ltd and a major legal judgment against Bioceres. Period-over-period data highlights ADARx's explosive 1,287.5% YoY collaboration revenue growth, but this is overshadowed by a 43.9% widening net loss. The most critical development is the Skyworks/Qorvo merger progressing with strong bondholder support (91-93% tendered), while HP's negative PC volume guidance signals headwinds for the tech hardware sector. Overall, the market is showing a high appetite for growth capital, but investors must carefully weigh this against mounting legal liabilities and insider profit-taking.

21 high priority 29 medium 50 total filings
· daily

New Federal Contractors — September 20, 2026

This digest covers a single civilian contract worth $309.3 million awarded to FCN, INC. by the Department of the Treasury (IRS) for Cisco IT and telecom support services. The contract is 100% civilian, with no defense exposure, and reflects the IRS's ongoing IT modernization priorities. The highest-conviction signal is bullish, driven by the multi-year revenue stream and set-aside advantage for a woman-owned small business. Key risks include execution risk under the firm-fixed-price structure and potential budget or modernization delays at the IRS.

1 total filings
· daily

Significant Contract Modifications ($10M+) — September 20, 2026

The sole significant contract modification in this period is a $309.3 million firm-fixed-price delivery order awarded to FCN, INC. by the Department of the Treasury (IRS), representing 100% of the total obligation and making this an entirely civilian-sector award. The contract, which runs through August 2027 with a total potential value of $388.4 million including options, underscores sustained federal investment in IT and telecom infrastructure modernization, specifically Cisco-related services. The highest-conviction signal is the multi-year revenue visibility for FCN, INC., though the firm-fixed-price structure introduces execution risk if costs overrun. Key watch items include option exercise announcements and any IRS budget adjustments or modernization delays that could alter contract scope. With no defense-related contracts in this period, the digest highlights civilian IT spending resilience, but concentration in a single award limits diversification for investors.

1 total filings
· daily

Contract Deobligations Alert — September 20, 2026

This digest covers a single, large civilian contract deobligation event totaling $309.3 million, with zero defense-related exposure. The dominant signal is a bullish award to FCN, INC. from the Department of the Treasury (IRS) for Cisco IT and telecom support services, representing a multi-year, firm-fixed-price revenue stream. The highest-conviction signal is the sheer size of the award relative to FCN's likely revenue base, signaling strong federal IT modernization demand. However, the key risk is the firm-fixed-price structure, which could compress margins if execution costs exceed estimates, and the contract's vulnerability to IRS budget fluctuations or modernization delays.

1 total filings
· daily

Contract Option Exercises — September 20, 2026

In the single contract recorded for September 20, 2026, FCN, INC. secured a $309.3 million firm-fixed-price delivery order from the IRS (Department of the Treasury) for Cisco IT and telecom support services, with a total potential value of $388.4 million including options. This is a civilian agency award, with zero defense-related contracts in the period, signaling continued strength in federal IT modernization outside the DOD. The contract, set aside for woman-owned small businesses, provides FCN with a multi-year revenue stream averaging $77.3 million annually through August 2027. The highest-conviction signal is the scale of the award relative to FCN's likely size, though execution risk on a fixed-price basis and IRS budget volatility are key watch items.

1 total filings